- Home
- MSB vs HRTX Comparison
MSB vs HRTX Comparison
Compare MSB & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSB
- HRTX
- Stock Information
- Founded
- MSB 1961
- HRTX 1983
- Country
- MSB United States
- HRTX United States
- Employees
- MSB N/A
- HRTX N/A
- Industry
- MSB Metal Mining
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- MSB Basic Materials
- HRTX Health Care
- Exchange
- MSB Nasdaq
- HRTX Nasdaq
- Market Cap
- MSB 320.9M
- HRTX 276.1M
- IPO Year
- MSB N/A
- HRTX 1987
- Fundamental
- Price
- MSB $30.92
- HRTX $1.35
- Analyst Decision
- MSB
- HRTX Strong Buy
- Analyst Count
- MSB 0
- HRTX 2
- Target Price
- MSB N/A
- HRTX $4.50
- AVG Volume (30 Days)
- MSB 48.2K
- HRTX 2.6M
- Earning Date
- MSB 01-01-0001
- HRTX 08-08-2025
- Dividend Yield
- MSB 22.43%
- HRTX N/A
- EPS Growth
- MSB 335.65
- HRTX N/A
- EPS
- MSB 7.12
- HRTX N/A
- Revenue
- MSB $25,894,592.00
- HRTX $149,694,000.00
- Revenue This Year
- MSB N/A
- HRTX $10.62
- Revenue Next Year
- MSB N/A
- HRTX $12.99
- P/E Ratio
- MSB $4.34
- HRTX N/A
- Revenue Growth
- MSB N/A
- HRTX 9.78
- 52 Week Low
- MSB $16.55
- HRTX $1.04
- 52 Week High
- MSB $37.00
- HRTX $2.68
- Technical
- Relative Strength Index (RSI)
- MSB 54.91
- HRTX 36.48
- Support Level
- MSB $30.68
- HRTX $1.33
- Resistance Level
- MSB $33.25
- HRTX $1.43
- Average True Range (ATR)
- MSB 1.06
- HRTX 0.07
- MACD
- MSB -0.24
- HRTX 0.02
- Stochastic Oscillator
- MSB 27.41
- HRTX 45.45
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.